The Supreme Court has raised fresh concerns over the pricing of medicines in India, focusing on the substantial difference that can exist between a medicine's price to retailers and its maximum retail price.
A bench of Justices Vikram Nath and Sandeep Mehta questioned why the 16% retailer margin used under India's existing drug-price control framework could not be considered more broadly across different categories of medicines.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: Supreme Court questions large differences between retailer prices and medicine MRPs.
Location: New Delhi.
Authority/Organisation: Supreme Court of India and Union Government.
Action Taken: Centre asked to examine the possibility of a broader uniform 16% margin framework.
Impact: The issue could affect medicine pricing and out-of-pocket healthcare costs if any regulatory changes are eventually introduced.
During the hearing, the court referred to an example involving a cancer medicine that was reportedly supplied to retailers for around ₹2,700 while carrying an MRP of about ₹27,000. The large difference prompted the bench to question the rationale behind such pricing gaps.
The court also asked the Centre to examine allegations that some corporate hospitals require patients to purchase medicines from their own or designated pharmacies. The bench noted that such practices could have wider financial implications when treatment costs are reimbursed through government-supported schemes.
The Centre told the court that consultations were required to find a workable approach that balances the interests of different stakeholders. The matter has been listed for further hearing on October 12, 2026.
Editorial Analysis
Why This Matters
Medicine pricing directly affects household healthcare expenditure, particularly for patients requiring long-term or expensive treatment. The court's observations have also brought attention to the relationship between medicine pricing, hospital pharmacy practices and government-funded healthcare reimbursements. However, any change to the existing pricing framework would require further examination by the government and potentially additional regulatory action. The court's current observations do not themselves establish a new pricing rule.
Importantly, the 16% figure discussed by the Supreme Court is not a new nationwide medicine-price cap at this stage. It is part of the court's questions and the proposed framework being examined in the ongoing proceedings.
